Palisade Bio Shares Are Trading Higher After the Company Announced the Presentation of Data From Two Studios Showing Ex Vivo Bioactivation of PALI-2108 in the Treatment of Ulcerative Colitis.
Palisade Bio Shares Are Trading Higher After the Company Announced the Presentation of Data From Two Studios Showing Ex Vivo Bioactivation of PALI-2108 in the Treatment of Ulcerative Colitis.
Palisade生物股票上漲，公司宣佈從兩個工作室展示的數據中展示了PALI-2108在潰瘍性結腸炎治療中的離體生物活化。
Palisade Bio Shares Are Trading Higher After the Company Announced the Presentation of Data From Two Studios Showing Ex Vivo Bioactivation of PALI-2108 in the Treatment of Ulcerative Colitis.
Palisade Bio股價上漲，公司宣佈從兩個研究所展示的數據中顯示，PALI-2108在潰瘍性結腸炎治療中的離體生物活化。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間